Lisata Therapeutics (LSTA) Equity Average (2016 - 2025)
Lisata Therapeutics (LSTA) has disclosed Equity Average for 11 consecutive years, with $19.1 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 46.59% year-over-year to $19.1 million, compared with a TTM value of $19.1 million through Sep 2025, down 46.59%, and an annual FY2024 reading of $38.6 million, changed N/A over the prior year.
- Equity Average was $19.1 million for Q3 2025 at Lisata Therapeutics, down from $22.9 million in the prior quarter.
- Across five years, Equity Average topped out at $59.2 million in Q2 2023 and bottomed at $19.1 million in Q3 2025.
- Average Equity Average over 3 years is $39.8 million, with a median of $40.4 million recorded in 2024.
- The sharpest move saw Equity Average decreased 10.71% in 2024, then plummeted 46.59% in 2025.
- Year by year, Equity Average stood at $50.3 million in 2023, then crashed by 37.62% to $31.4 million in 2024, then tumbled by 39.21% to $19.1 million in 2025.
- Business Quant data shows Equity Average for LSTA at $19.1 million in Q3 2025, $22.9 million in Q2 2025, and $27.2 million in Q1 2025.